Explore the latest in heart failure with preserved ejection fraction, including its pathophysiology, treatment, and long-term outcomes.
This Viewpoint discusses the emerging apparent association between COVID-19 and heart failure with preserved ejection fraction (HFpEF), and speculates on the pathophysiology and shared risk factors that may underlie the association and the possibility that SARS-CoV-2 infection may unmask or exacerbate existing HFpEF.
This randomized trial compares the effect of the oral soluble guanylate cyclase stimulator vericiguat (15 vs 10 mg/d) vs placebo on change in disease-specific physical function at 24 weeks among patients with HFpEF.
This randomized trial compares the safety and effect of the oral soluble guanylate cyclase stimulator praliciguat on functional capacity (peak V̇o2) at 8 weeks among patients with HFpEF.
This cross-sectional study examines clinician-assigned New York Heart Association (NYHA) classification vs patient-reported health status using the Kansas City Cardiomyopathy Questionnaire.
This Medical Letter review describes how tafamidis prevents transthyretin protein complexes from disocciating into amyloid fibrils, and its recent approval in 2 different formulations (Vyndaqel and Vyndamax) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
This systematic review summarizes the characteristic presentations, diagnosis, and management of immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis.
This cohort study of Japanese patients with acute decompensated heart failure examines the incidence and mode of postdischarge mortality among patients with reduced, midrange, and preserved ejection fraction.
This Viewpoint argues for the systematic identification of left atrium myopathy to guide tailored therapy in atrial fibrillation and heart failure with preserved ejection fraction.
The Viewpoint highlights the high price of treatment with tafamidis for people with transthyretin amyloidosis in the United States.
This cross-sectional study examines sex differences in cardiometabolic profiles and exercise hemodynamic profiles among individuals with heart failure with preserved ejection fraction.
This secondary analysis of the TOPCAT randomized clinical trial examines the association of β-blocker use with heart failure (HF) hospitalizations and cardiovascular disease (CVD) mortality, overall and in strata of patients with an ejection fraction (EF) of 50% or greater or less than 50%.
This case report describes a man in his 80s with left ventricular hypertrophy and enlarged biceps, as well as a diagnosis of hypertensive heart disease.
This cohort study assesses the reliability of sudden cardiac death prediction methods leading to prophylactic implantable cardioverter/defibrillator recommendations to reduce the number of sudden cardiac deaths occurring in patients with hypertrophic cardiomyopathy.
This cross-sectional study of data from the Atherosclerosis Risk in Communities (ARIC) study quantifies the association of undifferentiated dyspnea with cardiac dysfunction in older adults.
This dose-ranging phase 2b randomized trial compares the effects of neladenoson, a partial adenosine A1 receptor agonist, vs placebo on exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF).
This narrative review discusses the characteristic patterns of myocardial deformation or strain by speckle-tracking echocardiography found in patients with various forms of cardiac dysfunction and discusses prognostic implications.
This case-control study investigates whether if the normalized reciprocal of the plasma level of cardiac bridging integrator 1 protein differs in patients with heart failure with preserved ejection fraction, patients with risk factors for heart failure, and individuals with neither heart failure nor risk factors.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: